Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to show an improvement in overall survival in a lung cancer trial.

The Late Show with John Kerr Late-night music to comfort, connect and distract from the everyday challenges of life. Come on in - everyone’s welcome! With songs sentimental, slow and soothing… ...